Thursday 13th October 2022 |
Text too small? |
On 23 August 2022, Heartland Group Holdings Limited (NZX/ASX: HGH) (Heartland) advised the market that it expects net profit after tax (NPAT) for the financial year ending 30 June 2023 (FY2023) to be within the guidance range of $109 million to $114 million, excluding any impacts of fair value changes on equity investments held.
Heartland affirms that guidance range, but on the basis that the impact of the non-cash accounting item described below is also excluded from NPAT.
Impact of de-designation of derivatives on FY2023 NPAT
In the financial year ended 30 June 2022 (FY2022), Heartland took a one-off gain in relation to derivatives that were de-designated from hedge accounting relationships due to a change in interpretation of applicable technical accounting standards which Heartland was advised of during the audit of its FY2022 financial accounts. That gain was non-cash and, as advised to the market at the time, did not impact upon Heartland’s underlying earnings.
Whilst Heartland’s underlying earnings for FY2023 will not be impacted by the de-designation, Heartland is now aware that de-designation will give rise to a non-cash expense which will reduce FY2023 statutory reported NPAT by $6.6 million (and will also impact statutory reported NPAT in future reporting periods). As has been the case in prior years, further one-off items may arise during FY2023 to offset that expense in whole or in part.
Heartland does not consider the expense arising from the accounting treatment of derivatives to be material in the circumstances, particularly given that Heartland’s focus is on underlying earnings.
FY2023 guidance range
Heartland therefore affirms its expectation for statutory reported NPAT for FY2023 to be within the range of $109 million to $114 million, excluding any impacts of fair value changes on equity investments held and excluding the impact of the de-designation of derivatives described above.
– ENDS –
Update to forecast NPAT for FY2023
No comments yet
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report
RAD - Radius Care Announces On-market Share Buyback Programme
MCY - New wind farm propels MCY renewables commitment to $1b